Relapsing Polychondritis

4

Review clinical trials related to Relapsing Polychondritis. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis

Background: \- Vasculitis is a group of diseases that inflame and damage blood vessels and tissue. It can cause many medical problems. Few tests can diagnose the disease, and none can reliably predict a relapse. Researchers want to study people s genes and follow people over time to see how the disease affects them. Objective: \- To learn the signs, symptoms, imaging tests, genetic markers, and blood tests that can help identify people with vasculitis and predict what will happen to them over time. Eligibility: * People age 3 and older who have or are thought to have vasculitis, or are related to someone with it. * Healthy volunteers. Design: * Participants will be evaluated by a doctor who has expertise caring for patients with vasculitis. * Participants will give a blood sample. Some will give a urine sample. * Some participants may have brushings or biopsies taken from the inside lining of the nose. * Images of participants blood vessels may be taken using scans. For some scans, participants will lie on a table that moves in and out of a cylinder that takes pictures. For some scans, a contrast agent may be injected into an arm vein. Other scans may use a radioactive form of sugar. Healthy minors will not have scans. * Some participants will answer questionnaires. - Some participants will have their tests done at NIH. Others will have their doctor take the blood, saliva, or cheek swab samples and send them to NIH. * Some participants will have one visit lasting 1-2 (but sometimes up to 4) days. Some participants may have follow-up visits every 3 - 6 months, indefinitely.

Participants needed: 4,000
Trial details
Age: 3+Biological sex: AllType: ObservationalSponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Updated: Jun 16, 2026Locations: 1
Eligibility criteria

Subjects who fulfill modified versions of the 1990 American College of Rheumatol... [+3]

Subjects less than 3 years of age [+8]

Status: Recruiting

An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis

Open label pragmatic two-stage non-randomized trial comparing the effectiveness of five different standard of care treatment options for patients with relapsing polychondritis (RP).

Participants needed: 20
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: University of PennsylvaniaUpdated: Feb 4, 2026Locations: 1
Eligibility criteria

Bilateral auricular chondritis [+22]

Severe airway inflammation with supplemental oxygen requirement, tracheostomy, a... [+22]

Status: Recruiting

Longitudinal Study for Relapsing Polychondritis

Relapsing polychondritis (RP) is a rare systemic inflammatory disease characterized by recurrent inflammation of cartilage including ears, nose, tracheobronchial tree, chest wall and joints. Less commonly, it can cause inflammation of eyes, vasculature, nervous system, skin and inner ear. The purpose of this study is to study the pathogenesis of RP.

Participants needed: 100
Trial details
Biological sex: AllType: ObservationalSponsor: University of PennsylvaniaUpdated: Jan 23, 2026Locations: 1
Eligibility criteria

1. Any subject considered to have a diagnosis of relapsing polychondritis accord...

1. Inability to provide consent, or in the case of minors, assent.

Status: Recruiting

Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing Polychondritis

Relapsing polychondritis (RP) is a rare, systemic autoimmune disorder characterized by episodic inflammation of cartilaginous structures. The goal of this clinical trial is to learn if drug Upadacitinib works to treat relapsing polychondritis in adults. It will also learn about the safety of drug Upadacitinib. The main questions it aims to answer are: * Does drug Upadacitinib reduce the disease activity of relapsing polychondritis? * What medical problems do participants have when taking drug Upadacitinib? Researchers will compare drug Upadacitinib to conventional therapies (treatment with corticosteroids combined with immunosuppressants) to see if drug Upadacitinib works to treat relapsing polychondritis. Participants will: * Take drug Upadacitinib or corticosteroids combined with immunosuppressants every day for 24 weeks. * Visit the hospital once every month for checkups and tests. This clinical study will explore the efficacy and immunological evaluation of Upadacitinib in the treatment of RP.

Participants needed: 30
Trial details
Phase: Phase 1, Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Peking University People's HospitalUpdated: Mar 12, 2025Locations: 1
Eligibility criteria

1.Male or female ≥18 and ≤70 years [+4]

1.Use rituximab or other monoclonal antibodies within 2 months. [+11]